Navigation Links
The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer

ore commonly in the Eloxatin(R) combination arm. The incidence of increased bilirubin was similar on both arms. Changes noted on liver biopsies include: peliosis, nodular regenerative hyperplasia or sinusoidal alterations, perisinusoidal fibrosis and veno-occlusive lesions. Hepatic vascular disorders should be considered and, if appropriate, investigated in case of abnormal liver function test results or portal hypertension not explained by liver metastases * Monitoring of white blood cell count with differential, hemoglobin, platelet count and blood chemistries (including ALT, AST, bilirubin and creatinine) is recommended before each Eloxatin(R) cycle * The safety and effectiveness of Eloxatin(R) plus 5-FU/LV in patients with renal impairment have not been evaluated. Since the primary route of platinum elimination is renal, this combination should be used with caution in patients with preexisting renal impairment. Clearance of these products may be decreased by coadministration of potentially nephrotoxic compounds, although this has not been specifically studied * The incidence of diarrhea, dehydration, hypokalemia, leukopenia, fatigue and syncope were higher in patients .65 years old * Extravasation may result in local pain and inflammation that may be severe and lead to complications, including necrosis. Injection site reaction, including redness, swelling and pain, has been reported * There have been reports of prolonged prothrombin time and INR occasionally associated with hemorrhage in patients receiving Eloxatin(R) plus 5-FU/LV while on anticoagulants. Patients receiving Eloxatin(R) plus 5-FU/LV and requiring oral anticoagulants may require closer monitoring * The most common adverse reactions in patients with stage II or III colon cancer receiving adjuvant therapy were pe
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen
2. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
3. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
4. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
5. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
6. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
7. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
8. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
9. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
10. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
11. MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone
Post Your Comments:
(Date:8/1/2014)... , Aug. 1, 2014 Inovio Pharmaceuticals, Inc. ... a conference call to report its second quarter 2014 ... AM ET. CEO Dr. J. Joseph Kim ... quarter earnings, provide a corporate update, and participate in ... clinical development plans for VGX-3100, Inovio,s immune therapy targeting ...
(Date:8/1/2014)... -- DeepResearchReports.com adds "2014 Deep Research Report on ... Deep Research Report on Global and China Tricalcium ... Photo - http://photos.prnewswire.com/prnh/20140731/132164 ... Global and China Potassium Nitrate  Industry" is a ... China and Global Potassium Nitrate  market. ...
(Date:7/31/2014)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ; Sorrento) ... Chief Business Officer and Executive Vice President. Mr. Singh died ... "Sorrento is deeply saddened and shocked by the ... go to Amar,s family and friends," said Henry Ji ... Mr. Singh joined Sorrento in January 2014 from Synta ...
Breaking Medicine Technology:Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 2Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 4Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 5Sorrento Announces the Unexpected Death of its Chief Business Officer 2
... Society for Biomolecular Sciences Conference, THE WOODLANDS, ... Incorporated announced that data was presented,today highlighting ... Genentech, Inc. at the Society for Biomolecular,Sciences ... These target discoveries were made in a ...
... BASKING RIDGE, N.J., April 19, 2007 /PRNewswire-FirstCall/ ... company focused on acquiring, developing and,commercializing targeted ... of VQD- 002, a direct inhibitor of ... hematologic tumors.,Pre-clinical data was presented in a ...
Cached Medicine Technology:Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 2Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 3Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 4Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 5VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 2VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 4VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 5
(Date:8/1/2014)... August 01, 2014 The evolving ... independent community pharmacies. At ThoughtSpot 2014, AmerisourceBergen and ... with practices and resources to enhance patient care ... focused on critical issues to give independent pharmacists ... grow. , ThoughtSpot show attendance experienced a ...
(Date:8/1/2014)... Growing prevalence of chronic ailments, medical ... boosting healthcare market growth, although a reduction in ... generic consumption is a major challenge. , Turkey’s ... having grown at a Compound Annual Growth Rate ... the Health Transformation Program (Saglikta Donus, um Programi, ...
(Date:8/1/2014)... (HealthDay News) -- Patients with the progressive, deadly respiratory ... a new weapon to battle the disease, the U.S. ... agency approved a new treatment, an inhaled spray called ... of Americans. COPD, which is often linked to smoking, ... emphysema. Patients with COPD may experience a ...
(Date:8/1/2014)... August 01, 2014 For years, proponents ... A recent study conducted by the Ohio ... too far behind in terms of their health and ... know what’s best for their baby. So does this ... Dr. Steven Shapiro , chair of Pediatrics at ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Oxford ... company develops biomarkers. Its products include CytoSure heamatological ... +SNP Array, CytoSure ISCA UPD array, CytoSure ISCA ... array. OGT offers services, such as targeted sequencing ... service, miRNA analysis, gene expression analysis, cytosure services ...
Breaking Medicine News(10 mins):Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:FDA Approves New Treatment for People With COPD 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 3Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 2Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 3
... ... ... ... ...
... The U.S. ,race gap, in the commission of violent crime ... arrest rates for African Americans out-distancing those for whites concludes ... University and the University of Oregon. While the gap ... grew again in the ,80s with the advent of crack cocaine. ...
... ... of the New England ADHD Treatment Center are excited to announce a new five week ... ... and Dr. Jeffrey Speller of the New England ADHD Treatment Center are excited to ...
... ... “ADDY” Awards at the 2010 ADDY Awards Ceremony presented in Akron, ... program is the largest advertising competition in the world. With over ... arguably toughest advertising competition. The ADDY Awards represents the true spirit ...
... ... ... , ... , ...
... the rate of growth of the cancer tumour. The standard ... This is the conclusion of scientists at the University of ... The principal reason that patients die of cancer is the ... tumours known as metastases. These metastases are initially so small ...
Cached Medicine News:Health News:Want to Live a Healthier Lifestyle? Now There's an App for That, Too! 2Health News:Want to Live a Healthier Lifestyle? Now There's an App for That, Too! 3Health News:Want to Live a Healthier Lifestyle? Now There's an App for That, Too! 4Health News:Want to Live a Healthier Lifestyle? Now There's an App for That, Too! 5Health News:Violent crime 'race gap' narrows, but persists in US 2Health News:Violent crime 'race gap' narrows, but persists in US 3Health News:ADD Insights, LLC and The New England ADHD Treatment Center Announce a Joint Seminar Series: Mastering One's ADHD 2Health News:ADD Insights, LLC and The New England ADHD Treatment Center Announce a Joint Seminar Series: Mastering One's ADHD 3Health News:Lunar Cow Design Wins 4 Addy Awards From The American Advertising Federation 2Health News:Lunar Cow Design Wins 4 Addy Awards From The American Advertising Federation 3Health News:Special Session Highlights Late-Breaking Abstracts 2Health News:Special Session Highlights Late-Breaking Abstracts 3Health News:Special Session Highlights Late-Breaking Abstracts 4Health News:Special Session Highlights Late-Breaking Abstracts 5
... Ossur range of prefabricated foot and ankle ... - from ankle instability to foot malalignment. ... designs and energy-return technology., ,Age is ... ankle foot orthoses provide a measure of ...
... The Stabilizing Ankle support features ... which lock the calcaneus into ... eversion and inversion. The full-circumference ... and stability. Ideal for chronic ...
... Walker Pediatric Boot is the ... boot that offers superior comfort ... two sizes are offered thus ... will fit left or right, ...
... The Bledsoe PTB Boot is ... alternative to casting for the mid-tibia ... providing patella tendon bearing support. The ... designed for range of motion from ...
Medicine Products: